ロード中...
BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits pre-clinical activity in Philadelphia chromosome-positive leukemia
BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the cornerstone of treatment in chronic myeloid leukemia. Although there are now four TKIs approved for use in the front-line setting, acquired TKI resistance via secondary kinase domain mutations remains a problem for patients. K706 is a novel BCR-ABL1...
保存先:
| 出版年: | Exp Hematol |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6803074/ https://ncbi.nlm.nih.gov/pubmed/31493432 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.exphem.2019.08.007 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|